Umberto Veronesi is Scientific Director Emeritus of the European Institute of Oncology (EIO), Milan, Italy, which he founded in 1994. He was Minister of Health in the Italian Government from 2000 to 2001, and from 2008 to 2011 was a senator of the Italian Republic. Prof. Veronesi has devoted the greater part of his professional career to exploring new pathways of research with the aim of improving the treatment and quality of life of cancer patients, and he is responsible for a range of key innovations. He has also initiated educational enterprises for the training of oncologists, as founder of both the European School of Oncology and The European Society of Surgical Oncology. He has served as President of the International Union Against Cancer, of the European Organization for Research and Treatment of Cancer, and of the Federation of European Cancer Societies. He has been awarded 14 honorary degrees and is recipient of many honors and prizes, including the Gold Medal of the Italian Health Ministry. He is the author of more than 800 scientific publications and 12 oncological treatises.

Aron Goldhirsch is Deputy Scientific Director at the European Institute of Oncology, Milan, Italy. He has served as Co-Chairman of the Scientific Committee of the International Breast Cancer Study Group (IBCSG; formerly the Ludwig Group) and co-founder of the Breast International consortium (BIG). Since 1992 has been Professor for Medical Oncology at the University of Bern, Switzerland. Dr. Goldhirsch has received various international prizes and honors, including the prestigious St. Gallen International Breast Cancer Award (2013), the American Society of Clinical Oncology's Gianni Bonadonna Breast Cancer Award (2014), and the Komen Brinker Award for Scientific Distinction (co-recipient with Prof. Richard Gelber in 2008). He is the author of over 700 peer-reviewed articles and chapters in reference books, editor or co-editor of ten books, and he serves on

the editorial board of several oncology and breast cancer research journals.

Paolo Veronesi is Associate Professor of General Surgery at the University of Milan School of Medicine, and Director of the Breast Surgery Division at the European Institute of Oncology, Milan, Italy. He was deeply involved in the development of breast-conserving surgery and, more recently, in the development of the sentinel lymph node biopsy technique, intraoperative radiotherapy, and conservative mastectomy. Dr. Veronesi was President of the XXXIII Congress of the Italian Society of Surgical Oncology in June 2010. He has been President of the Umberto Veronesi Foundation for the progress of the science since 2005. He is the author of more than 240 papers and 25 book chapters, mainly in the field of breast diseases.

Maria Cristina Leonardi has worked at the Division of Radiation Therapy at the European Institute of Oncology, Milan, Italy since 1997; in 2009 she beca

me Deputy Director of the Division, having previously been Senior Assistant. Her main activities include 3D radiotherapy, intraoperative radiotherapy, intensity modulated radiotherapy and image-guided radiotherapy and she has been involved in numerous clinical studies involving breast and rectal cancer. Dr. Leonardi graduated in Medicine from the University of Milan in 1992 and subsequently completed her specialization in Radiation Oncology in 1996 at the Istituto Nazionale Tumori, Milan. She is a Member of the Italian Radiation Oncologists (AIRO) Breast Cancer Group and co-author of the Italian Guidelines on Breast Cancer. Currently, she is the national coordinator of the AIRO Working Group on Intraoperative Radiotherapy.

Oreste D. Gentilini was born in 1968. After 15 years at the European Institute of Oncology is now Head of Breast Surgery and Director of the Breast Unit at the San Raffaele University and Resea

rch Hospital, Milano. His interest and research commitments have focused on sentinel lymph node biopsy, breast cancer in young women, breast cancer during pregnancy and the possibility of extending the fields of breast conservation in special clinical scenarios. Dr. Gentilini is Chairman of the SOUND (Sentinel node vs Observation after axillary Ultra-souND) prospective, randomized, multicentre, international trial and author of more than 100 papers.

Describes all the important recent advances in the management of breast cancer

Covers progress in understanding of genetics and biology in detail

Designed to serve as a state-of-the-art reference for practitioners, residents, researchers, and advanced students

Part I An Integrated view of Breast Cancer Biology.- Fundamental pathways in breast cancer 1: signaling from the membrane.- Fundamental pathways in breast cancer 2: maintenance of genomic stability.-Fundamental pathways in breast cancer 3: estrogen biology.- Fundamental pathways in breast cancer 4: maintenance of epigenomic stability and the role of stem cells.- Breast cancer microenvironment and the metastatic process.- Mouse models of breast cancer.- Human mammary tumor virus proteins in human breast cancer cells.- Part II Epidemiology, Genetics and Prevention.- Epidemiology, life style and environment.- Genetic predisposition.- Chemoprevention.- Surgical prevention.- Part III Pathology: Standard and Molecular Diagnostics.- Premalignant lesions.- Prognostic and predictive role of genetic signatures.- Adding molecular information to immunohistochemistry.- Special types of breast cancer and nonepithelial tumors.- Pathology afterneoadjuvant treatments.- Breast cancer genomics.- Pathology report 2015.- Part IV Imaging.- Radiological screening of breast cancer. Evolution.- Innovation of radiological means for breast cancer.- Nuclear medicine in the clinical management (ROLL, SNB and PET).- One-step systemic staging for patients with breast cancer.- Imaging after breast surgery.- Integrated breast biopsy for best radiological diagnosis of breast cancer.- Part V Oncological Surgery.- Conservative surgery.- Conservative mastectomies.- Surgical treatment of reappearance of breast cancer.- Management of the axilla.- Management of intraepithelial disease.- Surgery after neoadjuvant therapies.- Surgery of primary tumor in stage IV breast cancers.- Local therapy for breast cancer in malignant lymphoma survivors.- Surgery of metastases.- Part VI Plastic and Reconstructive Surgery.- Oncoplastic surgery.- Delayed breast reconstruction.- Immediate breast reconstruction direct-to-implant.- Breast reconstruction with tissue expanders and definitive implant replacement.- Breast reconstruction with pedicled flaps.- Breast reconstruction with free flaps.- Contralateral breast management.- Fat grafting in breast reconstruction.- Breast reconstruction with biological and nonbiological meshes.- How to manage complications in breast reconstruction.- Part VII Medical Oncology.- Adjuvant systemic therapies by subtypes: guidelines.- Primary systemic therapies: guidelines.- Treatment of advanced disease: guidelines.- Endocrine therapies in the adjuvant and advanced disease settings.- Chemotherapy regimens in the adjuvant and advanced disease settings.- Anti-HER2 therapies in the adjuvant and advanced disease settings.- Systemic therapy with bisphosphonates and anti-RANK-L agents.- Systemic treatment for specific medical situations.- Part VIII Radiotherapy.- Conceptual basis and principles of radiation oncology.- Whole breast radiation following breast-conserving surgery in invasive cancer.- Whole breast radiation following breast-conserving surgery in noninvasive cancer.- Post-mastectomy radiotherapy.- Integration of radiotherapy with systemic therapies.- Partial breast irradiation.- Intraoperative radiotherapy ELIOT.- Radiotherapy for metastatic lesions.- Part IX Special Conditions Requiring Multidisciplinary Approaches.- Emergencies in breast cancer.- Breast cancer during pregnancy.- Fertility issues in patients with newly diagnosed breast cancer.- Sexual functions and breast cancer.- Male breast cancer.- Inflammatory breast cancer.- Treatment of CNS involvement.- Treatment of skeletal disease.- Follow-up of patients with breast cancer.- Part X Investigating New Drugs and Immunological Agents in Breast Cancer.- Targeting immune-checkpoint.- Targeting PIK3CA/AKT/mTOR.- Targeting genome instability and DNA repair.- Targeting CDK4/6 pathway.- Targeting FGFR pathway.- Integratingnext generation sequencing data in trial design.- Part XI Investigational and Miscellaneous Approaches.- Lifestyle and breast cancer.- Psychological support.- HIFU and radiofrequency as alternatives to surgery.- Hyperthermia with RT and with systemic therapies.- Electro-chemotherapy.- Circulating miRNA in early diagnosis.- Relevance of stem cells.- Part XII Biostatistics and Bioinformatics.- Subgroup analyses and information from clinical trials on breast cancer.- The methodology of meta analyses and its potential contribution to patient care.- Modern biostatistics for accelerated data acquisition for new drugs.- Bioinformatics for clinical use in breast cancer.- Efficacy endpoints in breast cancer studies.